Managing inadequate antidepressant response in depressive illness

British Medical Bulletin

Volumn 115, Issue 1, 2015, Pages 183-201

  Haddad, Peter M ^a,b   Talbot, Peter S ^a,c   Anderson, Ian M ^a   McAllister Williams, R Hamish ^d,e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e TYNE AND WEAR NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

antidepressants; antipsychotics; depression; ECT; lithium; neurostimulation therapies; treatment resistance

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; LIOTHYRONINE; LITHIUM; MIRTAZAPINE; MODAFINIL; PHENELZINE; NEUROLEPTIC AGENT;

ARTICLE; BRAIN DEPTH STIMULATION; COGNITIVE THERAPY; COMORBIDITY; ELECTROCONVULSIVE THERAPY; HUMAN; MAJOR DEPRESSION; NERVE STIMULATION; NEUROSURGERY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT DECISION MAKING; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RECURRENCE RISK; SOCIAL ASPECT; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT REFUSAL; TREATMENT RESPONSE; VAGUS NERVE STIMULATION; COMBINATION DRUG THERAPY; DEPRESSIVE DISORDER; DRUG RESISTANCE; DRUG SUBSTITUTION; MEDICATION COMPLIANCE; MULTIMODALITY CANCER THERAPY; PROCEDURES; PSYCHOTHERAPY; RISK FACTOR;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; COMBINED MODALITY THERAPY; COMORBIDITY; DEPRESSIVE DISORDER; DRUG RESISTANCE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; HUMANS; MEDICATION ADHERENCE; PSYCHOTHERAPY; RISK FACTORS; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84941195737     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldv034     Document Type: Article

References (106)

1. NICE (National Institute for Health and Care Excellence). Depression; the Treatment and Management of Depression in Adults (Update). NICE Clinical Guideline 90. NICE 2009. Available at www.nice.org.uk/CG90 (10 July 2015, date last accessed).
2. Cleare A, Pariante CM, Young AH, et al. members of the Consensus Meeting. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015;29:459-525.
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. Am J Psychiatry 2006;163:1905-17.
4. Malhi GS, Parker GB, Crawford J, et al. Treatment-resistant depression: resistant to definition? Acta Psychiatr Scand 2005;112:302-9.
5. Ruhé HG, van Rooijen G, Spijker J, et al. Staging methods for treatment resistant depression. A systematic review. J Affect Disord 2012;137:35-45.
6. Fekadu A, Wooderson S, Donaldson C, et al. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry 2009;70:177-84.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, D.C: American Psychiatric Association 2013.
8. Waraich P, Goldner EM, Somers JM, et al. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry 2004;49: 124-38.
9. Spijker J, de Graaf R, Bijl RV, et al. Duration of major depressive episodes in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J Psychiatry 2002;181:208-13.
10. Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003;12:3-21.
11. Thomas L, Kessler D, Campbell J, et al. Prevalence of treatment-resistant depression in primary care: cross-sectional data. Br J Gen Pract 2013;63:e852-8.
12. Rizvi SJ, Grima E, Tan M, et al. Treatment-resistant depression in primary care across Canada. Can J Psychiatry 2014;59:349-57.
13. Fostick L, Silberman A, Beckman M, et al. The economic impact of depression: resistance or severity? Eur Neuropsychopharmacol 2010;20:671-5.
14. Ivanova JI, Birnbaum HG, Kidolezi Y, et al. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr Med Res Opin 2010;26:2475-84.
15. Greenberg P, Corey-Lisle PK, Birnbaum H, et al. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics 2004;22: 363-73.
16. Fawcett J, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry 1983;44:8-11.
17. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus non-anxious depression: a STAR∗D report. Am J Psychiatry 2008;165:342-51.
18. Castaneda R, Sussman N, Westreich L, et al. A review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. J Clin Psychiatry 1996;57:207-12.
19. Fava M, Bouffides E, Pava JA, et al. Personality disorder comorbidity with major depression and response to fluoxetine treatment. Psychother Psychosom 1994;62: 160-7.
20. Patten SB, Love EJ. Can drugs cause depression? A review of the evidence. J Psychiatry Neurosci 1993; 18:92-102.
21. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003;60:39-47.
22. Kirmayer LJ, Robbins JM, Dworkind M, et al. Soma-tization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993;150:734-41.
23. Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med 2004;66:17-22.
24. Gartside SE, Leitch MM, Young AH. Altered gluco-corticoid rhythm attenuates the ability of a chronic SSRI to elevate forebrain 5-HT: implications for the treatment of depression. Neuropsychopharm 2003;28: 1572-8.
25. Bauer M, Pfennig A, Linden M, et al. Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression. J Clin Psychopharmacol 2009;29:327-33.
26. Zetin M, Hoepner CT. Relevance of exclusion criteria in antidepressant clinical trials: a replication study. J Clin Psychopharmacol 2007;27:295-301.
27. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25:1171-80.
28. Doraiswamy PM, Khan ZM, Donahue RM, et al. Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders. Am J Geriatr Psychiatry 2001;9:423-8.
29. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42:200-9.
30. Haddad PM, Brain C, Scott J. Nonadherence with anti-psychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 2014;5:43-62.
31. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201.
32. Demyttenaere K, Mesters P, Boulanger B, et al. Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine. J Affect Disord 2001; 65:243-52.
33. Kudlow PA, McIntyre RS, Lam RW. Early switching strategies in antidepressant non-responders: current evidence and future research directions. CNS Drugs 2014;28:601-9.
34. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:156-65.
35. Bauer M, El-Khalili N, Datto C, et al. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to anti-depressant therapy in patients with major depressive disorder. J Affect Disord 2010;127:19-30.
36. Furukawa T, McGuire H, Barbui C. Low dosage tricyc-lic antidepressants for depression. Cochrane Database Syst Rev 2003;3:CD003197.
37. Wade AG, Crawford GM, Yellowlees A. Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study. BMC Psychiatry 2011;11:42.
38. Thase ME, Shelton RC, Khan A. Treatment with venla-faxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard-and higher-dosing strategies. J Clin Psychopharmacol 2006; 26:250-8.
39. Mbaya P, Alam F, Ashim S, et al. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol 2007;22: 129-33.
40. Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs 2014;28:887-920.
41. Gaynes BN, Dusetzina SB, Ellis AR, et al. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR∗D. J Clin Psychopharmacol 2012;32:114-9.
42. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches. Biol Psychiatry 2008;63:699-704.
43. Bazire S. Psychotropic Drug Directory 2014: The Professionals' Pocket Handbook an Aide Memoire. Lloyd-Reinhold Communications LLP, 2014.
44. Haddad PM, Anderson IM. Recognising and managing antidepressant discontinuation symptoms. Adv Psych Treat 2007;13:447-57.
45. Palaniyappan L, Insole L, Ferrier IN. Combining antide-pressants: a review of evidence. Adv Psych Treat 2009;15:90-9.
46. Amsterdam JD, García-España F, Rosenzweig M. (1997) Clomipramine augmentation in treatment-resistant depression. Depress Anxiety 2009;5:84-90.
47. Davidson J, McLeod M, Law-Yone B, et al. A comparison of electroconvulsive therapy and combined phenelzine-ami-triptyline in refractory depression. Arch Gen Psychiatry 1978;35:639-42.
48. Tiller JW, Mitchell P, Burrows GD. Monoamine oxidase inhibitors (MAOI) or reversible inhibitors of monoamine oxidase (RIMA)/tricyclic antidepressant (TCA) combination therapy. Aust N Z J Psychiatry 1992;26:327-9.
49. Kennedy N, Paykel ES. Treatment and response in refractory depression: results from a specialist affective disorders service. J Affect Disord 2004;81:49-53.
50. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002;51:183-8.
51. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010;167:281-8.
52. Rush AJ, Trivedi MH, Stewart JW, et al. Combining Medications to Enhance Depression Outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011;168:689-701.
53. Warden D, Trivedi MH, Carmody T, et al. Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care. J Psychiatr Pract 2014;20: 118-32.
54. Bauer M, Adli M, Ricken R, et al. Role of lithium augmentation in the management of major depressive disorder. CNS Drugs 2014;28:331-42.
55. Bauer M, Bschor T, Kunz D, et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000;157: 1429-35.
56. Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013;346:f3646.
57. Bauer M, Dell'osso L, Kasper S, et al. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J Affect Disord 2013;151:209-19.
58. Aronson R, Offman HJ, Joffe RT, et al. Triiodothyron-ine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996;53: 842-8.
59. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009;166:980-91.
60. Goss AJ, Kaser M, Costafreda SG, et al. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 2013;74:1101-7.
61. Hale AS, Procter AW, Bridges PK. Clomipramine, trypto-phan and lithium in combination for resistant endogenous depression: seven case studies. Br J Psychiatry 1987;151:213-7.
62. Barker WA, Scott J, Eccleston D. The Newcastle chronic depression study: results of a treatment regime. Int Clin Psychopharmacol 1987;2:261-72.
63. Cusin C, Iovieno N, Iosifescu DV, et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry 2013;74:e636-41.
64. Faridhosseini F, Sadeghi R, Farid L, et al. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol 2014;29:216-23.
65. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003;64:403-7.
66. Santos MA, Rocha FL, Hara C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Prim Care Companion J Clin Psychiatry 2008;10:187-90.
67. Barbee JG, Thompson TR, Jamhour NJ, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry 2011; 72:1405-12.
68. Katalinic N, Lai R, Somogyi A, et al. Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry 2013;47:710-27.
69. Aan Het Rot M, Zarate CA Jr, Charney DS, et al. Keta-mine for depression: where do we go from here? Biol Psychiatry 2012;72:537-47.
70. Grosso G, Pajak A, Marventano S, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One 2014;9:e96905.
71. Almeida OP, Ford AH, Flicker L. Systematic review and meta-analysis of randomized placebo-controlled trials of folate and vitamin B12 for depression. Int Psychogeriatr 2015;3:1-11.
72. Bedson E, Bell D, Carr D, et al. Folate Augmentation of Treatment-Evaluation for Depression (FolATED): randomised trial and economic evaluation. Health Technol Assess 2014;18:vii-viii, 1-159.
73. Barth J, Munder T, Gerger H, et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. PLoS Med 2013;10:e1001454.
74. Cuijpers P, Berking M, Andersson G, et al. A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Can J Psychiatry 2013;58:376-85.
75. Cuijpers P, van Straten A, Warmerdam L, et al. Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. Depress Anxiety 2009;26:279-88.
76. Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry 1999;56:829-35.
77. Kennedy SH, Segal ZV, Cohen NL, et al. Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. J Clin Psychiatry 2003;64:439-44.
78. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR∗D report. Am J Psychiatry 2007;164:739-52.
79. Wiles N, Thomas L, Abel A, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet 2013;381:375-84.
80. DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005;62: 409-16.
81. Cuijpers P, Huibers M, Ebert DD, et al. How much psychotherapy is needed to treat depression? A metaregres-sion analysis. J Affect Disord 2013;149:1-13.
82. Biesheuvel-Leliefeld KE, Kok GD, Bockting CL, et al. Effectiveness of psychological interventions in preventing recurrence of depressive disorder: Meta-analysis and meta-regression. J Affect Disord 2014;174C: 400-10.
83. Kho KH, van Vreeswijk MF, Simpson S, et al. A meta-analysis of electroconvulsive therapy efficacy in depression. Journal of ECT 2003;19:139-47.
84. Pagnin D, de Queiroz V, Pini S, et al. Efficacy of ECT in depression: a meta-analytic review. Journal of ECT 2004;20:13-20.
85. UK ECT Review Group. Efficacy and safety of electro-convulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003;361:799-808.
86. Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. Journal of ECT 2001;17:244-53.
87. Heijnen WT, Birkenhäger TK, Wierdsma AI, et al. Anti-depressant pharmacotherapy failure and response to subsequent electroconvulsive therapy: a meta-analysis. J Clin Psychopharmacol 2010;30:616-19.
88. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 2001;285:1299-307.
89. Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry 2006;63:1337-44.
90. Jelovac A, Kolshus E, McLoughlin DM. Relapse following successful electroconvulsive therapy for major depression: a meta-analysis. Neuropsychopharmacology 2013;38:2467-74.
91. Kennedy SH, Milev R, Giacobbe P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. J Affect Disord 2009;117(Suppl 1):S44-53.
92. Kellner CH, Knapp R, Husain MM, et al. Bifrontal, bitemporal and right unilateral electrode placement in ECT: randomised trial. Br J Psychiatry 2010;196: 226-34.
93. Fitzgerald PB. Non-pharmacological biological treatment approaches to difficult-to-treat depression. Med J Aust 2013;199:S48-51.
94. Schutter DJ. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolat-eral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. Psychol Med 2009;39: 65-75.
95. Lam RW, Chan P, Wilkins-Ho M, et al. Repetitive tran-scranial magnetic stimulation for treatment-resistant depression: a systematic review and metaanalysis. Can J Psychiatry 2008;53:621-31.
96. Ren J, Li H, Palaniyappan L, et al. Repetitive transcra-nial magnetic stimulation versus electroconvulsive therapy for major depression: a systematic review and meta-analysis. Prog Neuropsychopharmacology Biol Psychiatry 2014;51:181-9.
97. Rizvi SJ, Donovan M, Giacobbe P, et al. Neurostimula-tion therapies for treatment resistant depression: a focus on vagus nerve stimulation and deep brain stimulation. Int Rev Psychiatry 2011;23:424-36.
98. Moreines JL, McClintock SM, Holtzheimer PE. Neu-ropsychologic effects of neuromodulation techniques for treatment-resistant depression: a review. Brain Stimul 2011;4:17-27.
99. Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005;58:347-54.
100. Shuchman M. Approving the vagus-nerve stimulator for depression. New Engl J Med 2007;356:1604-7.
101. Martin JLR, Martin-Sanchez E. Systematic review and meta-analysis of vagus nerve stimulation in the treatment of depression: variable results based on study designs. European Psychiatry 2012;27:147-55.
102. NICE (National Institute for Health and Care Excellence). Vagus Nerve Stimulation for Treatment-Resistant Depression. NICE Interventional Procedure Guidance IPG330. NICE 2009. Available at: www.nice.org. uk/guidance/ipg330 (10 July 2015, date last accessed).
103. Dougherty DD, Rezai AR, Carpenter LL, et al. A Randomized Sham-Controlled Trial of Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Chronic Treatment-Resistant Depression. Biol Psychiatry 2015;78:240-8.
104. Patel SR, Aronson JP, Sheth SA, et al. Lesion procedures in psychiatric neurosurgery. World Neurosurg 2013;80: S31.e39-16.
105. Shepherd DJ, Insole LJ, McAllister-Williams RH, et al. Are specialised affective disorder services useful? Psychiatrist Bull 2009;33:41-3.
106. Wooderson SC, Juruena MF, Fekadu A, et al. Prospective evaluation of specialist inpatient treatment for refractory affective disorders. J Affect Disord 2011;131:92-103.